TR200102497T2 - Yeni streptococcus antijenleri - Google Patents

Yeni streptococcus antijenleri

Info

Publication number
TR200102497T2
TR200102497T2 TR2001/02497T TR200102497T TR200102497T2 TR 200102497 T2 TR200102497 T2 TR 200102497T2 TR 2001/02497 T TR2001/02497 T TR 2001/02497T TR 200102497 T TR200102497 T TR 200102497T TR 200102497 T2 TR200102497 T2 TR 200102497T2
Authority
TR
Turkey
Prior art keywords
proteins
streptococcus
streptococcus antigens
new streptococcus
new
Prior art date
Application number
TR2001/02497T
Other languages
English (en)
Inventor
Hamel Josee
R. Brodeuer Bernard
Pineau Isabelle
Martin Denis
Rioux Clement
Charland Nathalie
Original Assignee
Shire Biochem Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102497(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Biochem Inc. filed Critical Shire Biochem Inc.
Publication of TR200102497T2 publication Critical patent/TR200102497T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Streptococcus proteinleri ve bu proteinleri kodlayan polinükleotidler anlatilmistir. Bahsedilen proteinler antijeniktir ve bu yüzden, hayvanlarda streptococcus enfeksiyonunun terapisi ya da profilaksi için yararli asi bilesenleridir. Ayni zamanda, protein antijenlerinin üretilmesi için rekombinant yöntemlerin yanisira streptococcus bakteryel enfeksiyonunun bulgulanmasi için teshis tahlilleri de anlatilmistir.
TR2001/02497T 1998-12-23 1999-12-20 Yeni streptococcus antijenleri TR200102497T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
TR200102497T2 true TR200102497T2 (tr) 2002-01-21

Family

ID=22351610

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/02497T TR200102497T2 (tr) 1998-12-23 1999-12-20 Yeni streptococcus antijenleri
TR2002/00633T TR200200633T2 (tr) 1998-12-23 1999-12-20 Yeni streptococcus antijenleri

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/00633T TR200200633T2 (tr) 1998-12-23 1999-12-20 Yeni streptococcus antijenleri

Country Status (29)

Country Link
EP (2) EP2261358B1 (tr)
JP (2) JP4761623B2 (tr)
KR (4) KR100802198B1 (tr)
CN (3) CN100398653C (tr)
AP (1) AP2001002199A0 (tr)
AR (1) AR029322A1 (tr)
AT (1) ATE394489T1 (tr)
AU (1) AU1764900A (tr)
BR (1) BR9916477A (tr)
CA (1) CA2356836C (tr)
CL (1) CL2009002037A1 (tr)
CY (3) CY1108223T1 (tr)
CZ (2) CZ302790B6 (tr)
DE (1) DE69938670D1 (tr)
DK (3) DK2261358T3 (tr)
EA (1) EA007409B1 (tr)
ES (3) ES2306528T3 (tr)
HU (1) HU229664B1 (tr)
IL (3) IL143905A0 (tr)
MX (1) MXPA01006427A (tr)
NO (1) NO330800B1 (tr)
NZ (1) NZ512574A (tr)
OA (1) OA11736A (tr)
PL (3) PL205041B1 (tr)
PT (3) PT1141306E (tr)
TR (2) TR200102497T2 (tr)
UY (1) UY25877A1 (tr)
WO (1) WO2000039299A2 (tr)
ZA (1) ZA200105114B (tr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002437T2 (tr) 1998-02-20 2000-11-21 Biochem Pharma Inc. B grubu streptococcus antijenleri.
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
DE69940439D1 (de) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
KR100802198B1 (ko) * 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원
ES2316450T3 (es) 2000-06-12 2009-04-16 University Of Saskatchewan Proteina gapc quimerica de streptococcus y su uso en vacunacion y diagnostico.
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
WO2002079475A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
WO2003004650A2 (en) * 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1456231A2 (en) 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
EP1601770B1 (en) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
EP2333114A1 (en) * 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101802198B (zh) * 2007-07-23 2016-02-17 圣诺菲·帕斯图尔有限公司 免疫原性多肽和单克隆抗体
US20120164178A1 (en) 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
DK2473605T3 (en) 2009-09-03 2018-05-28 Pfizer Vaccines Llc PCSK9-VACCINE
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
WO2012100234A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
WO2013102641A1 (en) * 2012-01-05 2013-07-11 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers
WO2014089706A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
PT656014E (pt) * 1993-03-19 2003-09-30 Gunnar Lindahl Proteina rib, uma proteina da superficie celular que confere imunidade a muitas estirpes de estreptococos do grupo b: processo para purificacao da proteina, estojo de reagentes e composicao farmaceutica
AU700080B2 (en) * 1995-06-07 1998-12-17 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the HSP70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
CA2271720A1 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
AU9510598A (en) * 1997-09-24 1999-04-12 American Cyanamid Company Human complement c3-degrading proteinase from (streptococcus pneumoniae)
AU770378B2 (en) * 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
WO2000006738A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
EP1100921B1 (en) * 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
BR9914066A (pt) * 1998-09-24 2002-04-23 Univ Minnesota Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
DE69940439D1 (de) * 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
KR100802198B1 (ko) * 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원

Also Published As

Publication number Publication date
WO2000039299A3 (en) 2000-11-02
PT1950302E (pt) 2013-01-16
CY1115340T1 (el) 2017-01-04
KR100802198B1 (ko) 2008-02-11
KR101078919B1 (ko) 2011-11-01
EP2261358B1 (en) 2014-05-14
AR029322A1 (es) 2003-06-25
KR20080036666A (ko) 2008-04-28
MXPA01006427A (es) 2002-06-04
KR101170203B1 (ko) 2012-07-31
HUP0104774A3 (en) 2007-10-29
PL206576B1 (pl) 2010-08-31
KR20100063814A (ko) 2010-06-11
EP1141306A2 (en) 2001-10-10
BR9916477A (pt) 2004-06-22
ZA200105114B (en) 2002-11-21
TR200200633T2 (tr) 2002-06-21
CN1191362C (zh) 2005-03-02
CN1332803A (zh) 2002-01-23
CN101134775A (zh) 2008-03-05
JP4761623B2 (ja) 2011-08-31
UY25877A1 (es) 2000-08-21
PT2261358E (pt) 2014-07-30
HUP0104774A2 (hu) 2002-04-29
CA2356836A1 (en) 2000-07-06
CY1108223T1 (el) 2014-02-12
EP2261358A2 (en) 2010-12-15
WO2000039299A2 (en) 2000-07-06
ES2480417T3 (es) 2014-07-28
DK1141306T3 (da) 2008-08-18
EA200100565A1 (ru) 2002-04-25
PL205041B1 (pl) 2010-03-31
HU229664B1 (en) 2014-04-28
NO20013045D0 (no) 2001-06-19
EP1141306B1 (en) 2008-05-07
KR20010104693A (ko) 2001-11-26
PT1141306E (pt) 2008-07-30
CZ302790B6 (cs) 2011-11-09
AP2001002199A0 (en) 2001-09-30
JP5039802B2 (ja) 2012-10-03
DK1950302T3 (da) 2013-01-14
NO330800B1 (no) 2011-07-18
ATE394489T1 (de) 2008-05-15
CL2009002037A1 (es) 2010-06-25
ES2306528T3 (es) 2008-11-01
JP2010142246A (ja) 2010-07-01
CA2356836C (en) 2011-09-13
EA007409B1 (ru) 2006-10-27
KR20060134227A (ko) 2006-12-27
KR100891398B1 (ko) 2009-04-02
CZ303675B6 (cs) 2013-02-27
AU1764900A (en) 2000-07-31
CY1114722T1 (el) 2016-10-05
DK2261358T3 (da) 2014-07-28
IL194230A (en) 2013-12-31
JP2002533123A (ja) 2002-10-08
PL204073B1 (pl) 2009-12-31
ES2400280T3 (es) 2013-04-08
HK1118575A1 (en) 2009-02-13
CZ20012161A3 (cs) 2001-10-17
NZ512574A (en) 2004-03-26
EP2261358A3 (en) 2011-02-23
NO20013045L (no) 2001-08-20
OA11736A (en) 2005-06-12
PL349777A1 (en) 2002-09-09
DE69938670D1 (de) 2008-06-19
IL143905A0 (en) 2002-04-21
CN1654657A (zh) 2005-08-17
IL143905A (en) 2011-05-31
CN100398653C (zh) 2008-07-02
IL194230A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
TR200200633T2 (tr) Yeni streptococcus antijenleri
MXPA03000103A (es) Antigenos de streptococcus.
AP2000001886A0 (en) Group B streptococcus antigens.
DE69739981D1 (de) Streptococcus pneumoniae-Antigene und Impfstoffe
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
DE69728897D1 (de) Saeugetierchemokine
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
PT917471E (pt) Tratamento e diagnostico de infeccoes por cocci gram-positivo
GB9810084D0 (en) Proteins
ATE281524T1 (de) Moraxella catarrhalis pilq proteine
TR200003608T2 (tr) Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri.
EP1950302A3 (en) Streptococcus antigens
ATE547527T1 (de) Gruppe b streptococcus bvh-a2 und bvh-a3 antigene
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
EP1219635A3 (en) Chlamydia pneumoniae antigenes
NO970130L (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener
BR0111886A (pt) Antìgeno para estreptococos
ATE293693T1 (de) Moraxella catarrhalis antigen basb117
ATE293692T1 (de) Moraxella catarrhalis antigen basb120